Any current/future new fundraising through debt or equity?

The company is currently not planning large-scale acquisitions funded directly from its balance sheet due to leverage concerns. For smaller bolt-on acquisitions or partnerships, the company is open and able to finance these without strain. There is a committed principal promoter and investor support, so financing larger transactions through different structures (not necessarily on the balance sheet) is possible. No explicit current or future plans were shared regarding raising new equity. Debt restructuring has simplified borrowing and created additional lines for future support, implying read

Any current/future capex/capital investment/strategic investment?

The company has completed most of its significant capex investments in the last few years, establishing a base to support business growth for the next several years. For the current financial year (FY ’25), capex is expected to be subdued and in the range of INR 50 crores to INR 60 crores, primarily to support global formulation opportunities. Strategic investments focus on inorganic growth through disciplined M&A primarily in companion animal formulations and bolt-on brands or licensing partnerships. On the API side, the company looks for acquisitions that can strengthen or shorten R&D time-t

Future growth expectations in sales/revenue/volumes?

The company targets early double-digit top-line growth over the next 2 to 3 years, aiming for 10% to 12% revenue growth annually. Growth drivers include approximately one-third volume growth, one-third price increases, and one-third from new products and launches. Formulation business volumes are expected to grow around 5% to 7% across most markets. The Turkey business is expected to grow in volume while maintaining pricing discipline, with exports from Turkey increasing, especially to Middle East and North Africa. The India formulation business is poised for growth with recent team expansions

Future growth expectations in earnings/operating earnings/profits/EPS?

SeQuent Scientific targets early double-digit top-line growth over the next 2-3 years. EBITDA margins are expected to reach mid-teens by the end of FY '25 and progress to high teens subsequently. The company aims for consistent, profitable, and sustainable growth driven by operational excellence and portfolio expansion. Margin improvements are supported by operational efficiencies, pricing actions, and portfolio rationalization. The company foresees margin and profit growth from geographic expansions, especially in Europe and Turkey. Debt levels are expected to reduce substantially o

Viyash ScientificQ1 FY25Pharmaceuticals & Biotechnology

Viyash Scientific Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹232P/E: 48.7Market Cap: ₹10.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company targets early double-digit top-line growth over the next 2 to 3 years, aiming for 10% to 12% revenue growth annually.
Growth drivers include approximately one-third volume growth, one-third price increases, and one-third from new products and launches.
Formulation business volumes are expected to grow around 5% to 7% across most markets.
The Turkey business is expected to grow in volume while maintaining pricing discipline, with exports from Turkey increasing, especially to Middle East and North Africa.
The India formulation business is poised for growth with recent team expansions and new product launches expected to accelerate revenue in the next 12 to 18 months.
The European market showed strong 34% YoY growth, supported by new business opportunities and portfolio restructuring.
The vaccine business is seen as a new growth avenue, with plans to add more products over the next 12 to 24 months.
Overall, the company expects to sustain growth momentum while optimizing working capital and operational efficiencies.

Margin guidance

Category 1

SeQuent Scientific targets early double-digit top-line growth over the next 2-3 years.
EBITDA margins are expected to reach mid-teens by the end of FY '25 and progress to high teens subsequently.
The company aims for consistent, profitable, and sustainable growth driven by operational excellence and portfolio expansion.
Margin improvements are supported by operational efficiencies, pricing actions, and portfolio rationalization.
The company foresees margin and profit growth from geographic expansions, especially in Europe and Turkey.
Debt levels are expected to reduce substantially over 3 years, lowering interest costs and supporting earnings improvement.
India formulations and companion animal businesses are key growth areas targeted to rise from less than 5% to ~15% over 3-5 years.
Inorganic growth (M&A/licensing) could accelerate earnings depending on execution and market conditions.

See what Viyash Scientific management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company is currently not planning large-scale acquisitions funded directly from its balance sheet due to leverage concerns.
For smaller bolt-on acquisitions or partnerships, the company is open and able to finance these without strain.
There is a committed principal promoter and investor support, so financing larger transactions through different structures (not necessarily on the balance sheet) is possible.
No explicit current or future plans were shared regarding raising new equity.
Debt restructuring has simplified borrowing and created additional lines for future support, implying readiness for funding if required.
Overall, finance availability is not expected to be a challenge for strategic opportunities, but no formal new fundraising (debt or equity) announcements were made.

Order book

The transcript does not provide specific details on the current or expected order book or pending orders for SeQuent Scientific Limited. However, relevant insights related to business outlook and growth include: - The company is experiencing strong growth, particularly in Europe and emerging markets like Turkey. - There is increased demand due to disease outbreaks and new product introductions. - The company is expanding its formulations business in India, expecting accelerated growth in 12 to 18 months. - Exports from Turkey are increasing, supporting foreign exchange and operational efficiencies. - Focus on organic growth supported by potential bolt-on acquisitions and partnerships. - Management emphasizes agile response to market conditions, with stable expected volume growth of 5-7% in existing portfolios. No explicit numeric data or order book size figures are mentioned in the provided pages.

See what Viyash Scientific management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has completed most of its significant capex investments in the last few years, establishing a base to support business growth for the next several years.
For the current financial year (FY ’25), capex is expected to be subdued and in the range of INR 50 crores to INR 60 crores, primarily to support global formulation opportunities.
Strategic investments focus on inorganic growth through disciplined M&A primarily in companion animal formulations and bolt-on brands or licensing partnerships.
On the API side, the company looks for acquisitions that can strengthen or shorten R&D time-to-market, improve scale, or internalize operations for profitability.
There are no large-scale acquisitions planned immediately due to current leverage, but the company is open to smaller bolt-on deals and partnerships.
Financing options are available through committed investors and alternate structures, so finance is not seen as a barrier for strategic opportunities.

Track Viyash Scientific — get its next earnings analysis in your feed

How does Viyash Scientific rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisViyash Scientific

Rev 3Mar 1

See where Viyash Scientific sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Viyash Scientific rank in Pharmaceuticals & Biotechnology?

Compare Viyash Scientific against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Viyash Scientific's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →